Full-Time
Head of Product Management Cell Therapy Solutions
Multiple Teams
Updated on 9/4/2026
Sartorius
5,001-10,000 employees
Laboratory instruments and bioprocess solutions
No salary listed
Freiburg im Breisgau, Germany + 3 more
More locations: Göttingen, Germany | Aubagne, France | Nottingham, UK
Hybrid
Possibility to work remotely some days per week.
Master's, MBA
 Product (1) |
|---|
Get referred to Sartorius
See people who can refer or advise you
- A Master’s degree in Life Sciences, Biotechnology, Biomedical Engineering, Business, Marketing or a related field is required.
- Extensive professional experience in Life Sciences and a proven track record in product management are required, including experience in customer-facing business environments and people leadership.
- The ability to lead teams, establish accountability and align diverse stakeholders around common priorities is required.
- A strong understanding of the advanced therapies market is required, including knowledge of cell therapy customer segments, therapeutic and manufacturing workflows, market dynamics, competitive developments and industry trends.
- Strong analytical, strategic thinking, problem-solving and decision-making skills are required.
- Strong communication, presentation and networking skills are required, including the ability to engage effectively with senior stakeholders.
- The ability to work in a fast-paced, dynamic environment while managing multiple priorities and driving execution is required.
- Develop and implement the product strategy for the assigned product cluster in alignment with company goals and objectives, ensuring clear prioritization, focus and sustainable portfolio growth.
- Foster collaboration within the Product Management team and across Product Development, Operations, Sales, Marketing and other cross-functional stakeholders to drive execution and business impact.
- Champion the assigned product cluster with senior leadership and key stakeholders, regularly communicating strategy, performance, opportunities and challenges.
- Define, monitor and review relevant portfolio and business key performance indicators, proactively identifying opportunities, corrective actions and performance improvements.
- Lead and develop a team of Product Managers, ensuring accountability for portfolio success across the entire product lifecycle and promoting a high-performance mindset.
- Conduct regular business and portfolio reviews to assess customer needs, market opportunities and business impact while providing recommendations for continuous improvement.
- Partner with Operations to ensure visibility of portfolio priorities, exceptions and demand-related topics and support alignment across the value chain.
- Leverage customer insights, market intelligence, competitive dynamics and emerging technologies to identify unmet needs and growth opportunities for the assigned product cluster.
- Drive innovation through cross-functional collaboration, rapid evaluation of new concepts and validation of customer value propositions.
- Promote a Sartorius-first mindset in portfolio planning and prioritization activities, ensuring resources and investments are focused on opportunities that create the greatest long-term value for the business.
- An MBA or equivalent business qualification is strongly desired.
Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Göttingen, Germany
Founded
1870
Get referred to Sartorius
See people who can refer or advise you
Simplify's Take
What believers are saying
- H1 2026 sales grew 7.7% operationally; underlying EBITDA margin reached 30.3%.
- Management confirmed 2026 guidance after Q1 2026 and H1 2026 results.
- Employee count rose to 14,279 by June 30, 2026, signaling active hiring.
What critics are saying
- Reuters on July 23, 2026 said growth lands in the lower half.
- U.S. tariff refunds forced customer reimbursements, hitting 2026 revenue and margins.
- Gator Bio beat Sartorius in 2026 U.S. patent rulings, weakening bioanalytical defensibility.
What makes Sartorius unique
- Sartorius monetizes recurring bioprocess consumables, not just lumpy capital equipment.
- Ann Arbor’s $100 million bioanalytics center deepens U.S. service and application support.
- SIMCA and SIMCA-online embed Sartorius into process monitoring workflows at biopharma plants.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget
Company News
Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.
Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.
Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.
May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.
Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.